Our Approach

Ardelyx develops:

Drugs that target proteins found in the gut whose activities affect the entire body
Drugs that are not absorbed, enabling them to achieve systemic efficacy while avoiding systemic toxicity and side effects

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

Ardelyx News

08/31/2011
Ardelyx, Inc. Closes $30M Series B Financing

08/31/2011
Ardelyx Appoints Mark Kaufmann To Chief Business Officer

08/08/2011
Ardelyx will present at the American College of Gastroenterology Annual Scientific Meeting on October 28 - November 2, 2011 in Washington, DC

» See all news

Reduce systemic uptake, minimize side effects.

Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. Our molecules, whose systemic exposure is severely restricted, exploit natural mechanisms of nutrient transport and solute sensing occurring through intestinal epithelia.

Product Pipeline

Program	Indication	Pre-Clin.	Phase 1	Phase 2	Phase 3
RDX5791	IBS-C	*	*	*	*
RDX5791	Hypertension	*	*	*	*
RDX008	Hypertension	*	*	*	*
RDX002	CKD	*	*	*	*
RDX009	Diabetes	*	*	*	*